Tracon Pharmaceuticals Overview

  • Founded
  • 2004

Founded
  • Status
  • Public

  • Employees
  • 35

Employees
  • Stock Symbol
  • TCON

Stock Symbol
  • Share Price
  • $1.72

  • (As of Tuesday Closing)

Tracon Pharmaceuticals General Information

Description

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, TJ4309, Bispecific Antibodies.

Contact Information

Formerly Known As
Lexington Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 4350 La Jolla Village Drive
  • Suite 800
  • San Diego, CA 92122
  • United States
+1 (858) 000-0000

Tracon Pharmaceuticals Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tracon Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.72 $1.68 $1.24 - $4.14 $36.8M 21.4M 58.6K -$1.57

Tracon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 25,218 26,043 148,083 (5,736)
Revenue 0 346 0 0
EBITDA (30,231) (28,349) (16,230) (22,272)
Net Income (30,367) (28,667) (16,775) (22,674)
Total Assets 15,677 26,557 37,438 18,121
Total Debt 0 1,538 4,527 5,698
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tracon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tracon Pharmaceuticals‘s full profile, request access.

Request a free trial

Tracon Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tracon Pharmaceuticals‘s full profile, request access.

Request a free trial

Tracon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targ
Drug Discovery
San Diego, CA
35 As of 2022
00000
000000000 00000

000000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
000000000000000
Boulder, CO
000 As of 0000
00000
000000&0

000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
000000000000000
Gothenburg, Sweden
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tracon Pharmaceuticals Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clovis Oncology Formerly VC-backed Boulder, CO 000 00000 000000&0
000000 000000 0000 Formerly VC-backed Gothenburg, Sweden 00 000.00 000000000 000.00
00000 00000000000 Formerly VC-backed Hayward, CA 000 00000 000000000 00000
00000000 Formerly VC-backed Rockville, MD 0 000.00 000000000 000.00
0000000 Venture Capital-Backed Groningen, Netherlands 0 00.000 000
You’re viewing 5 of 10 competitors. Get the full list »

Tracon Pharmaceuticals Patents

Tracon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9926375-B2 Anti-endoglin antibodies and uses thereof Inactive 12-Nov-2014 00000000000
US-20190016815-A1 Anti-endoglin antibodies and uses thereof Inactive 12-Nov-2014 00000000000
US-20160257755-A1 Anti-endoglin antibodies and uses thereof Active 12-Nov-2014 00000000000
AU-2015346444-A1 Anti-endoglin antibodies and uses thereof Inactive 12-Nov-2014 00000000000
CA-2966905-A1 Anti-endoglin antibodies and uses thereof Inactive 12-Nov-2014 C07K16/2896
To view Tracon Pharmaceuticals’s complete patent history, request access »

Tracon Pharmaceuticals Executive Team (13)

Name Title Board Seat Contact Info
Charles Theuer MD Chief Executive Officer & Chairman
Scott Brown Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Shahe Garabedian Senior Vice President, Quality Assurance
James Freddo MD Chief Medical Officer
Lisa Johnson-Pratt Board of Director
You’re viewing 5 of 13 executive team members. Get the full list »

Tracon Pharmaceuticals Board Members (16)

Name Representing Role Since
Carol Lam Tracon Pharmaceuticals Board Member 000 0000
Charles Theuer MD Tracon Pharmaceuticals Chief Executive Officer & Chairman 000 0000
J. Twiford Ph.D Brookline Group Board Member 000 0000
Martin Mattingly Ph.D Tracon Pharmaceuticals Board Member 000 0000
Paul Walker New Enterprise Associates Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Tracon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial